Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

• Published in: Cardiovascular diabetology Vol. 20; no. 1; p. 94
• Main Authors: Lorenzatti, Alberto J, Monsalvo, Maria Laura, López, J Antonio G, Wang, Huei, Rosenson, Robert S
• Format: Journal Article
• Language: English
• Published: England BioMed Central 30.04.2021; BMC
• Subjects: Apolipoprotein B; Arteriosclerosis; Atherogenic dyslipidemia; Cardiovascular disease; Cardiovascular diseases; Cholesterol; Clinical trials; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Drug dosages; Dyslipidemia; Evolocumab; Heart attacks; High density lipoprotein; Insulin resistance; Lipid-lowering therapy; Lipids; Lipoproteins; Lipoproteins (very low density); Low density lipoprotein; Metabolic disorders; Metabolic syndrome; Monoclonal antibodies; Original Investigation; Placebos; Statins; Treatment goals; Atherogenic dyslipidemia; Lipoproteins; Diabetes mellitus; Evolocumab; Cardiovascular disease; PCSK9 inhibition; Lipid-lowering therapy
• ISSN: 1475-2840; 1475-2840
• DOI: 10.1186/s12933-021-01287-6

Atherogenic dyslipidemia (AD), characterized by increased concentrations of apolipoprotein B (ApoB)-containing particles, is often present in individuals with type 2 diabetes mellitus (T2DM). Non-high-density lipoprotein cholesterol (non-HDL-C), cholesterol transported by apolipoprotein B (ApoB)-containing particles), and total apoB are considered secondary goals of lipid-lowering therapy to guide treatment of residual cardiovascular risk. The BANTING and BERSON studies demonstrated that evolocumab added to statin therapy reduced atherogenic lipid and lipoproteins concentrations in patients with T2DM. This post-hoc analysis combined data from two randomized, placebo-controlled trials, BANTING and BERSON, to investigate the effect of evolocumab (140 mg every two weeks [Q2W] or 420 mg monthly [QM]) on atherogenic lipid (LDL-C, non-HDL-C, VLDL-C, remnant cholesterol) and lipoproteins (ApoB, lipoprotein(a) (Lp[a])), and achievement of 2019 European Society of Cardiology/European Atherosclerosis Society lipid treatment goals in individuals with and without AD. In individuals with high TGs with (n = 389) and without (n = 196) AD receiving background statin therapy, evolocumab, compared with placebo, substantially reduced the cholesterol levels from all ApoB atherogenic lipoproteins (least squares (LS) mean LDL-C by 66.7% to 74.3%, non-HDL-C by 53.4% to 65.8%, median remnant cholesterol by 28.9% to 34.2%, VLDL-C by 16.1% to 19.6%) and median TGs levels (by 17.5% to 19.6%) at the mean of weeks 10 and 12. LS mean ApoB was significantly reduced by 41.5% to 56.6% at week 12. Results were consistent in diabetic individuals with normal TGs (n = 519). Evolocumab was also associated with a significant reduction in median Lp(a) by 35.0% to 53.9% at the mean of weeks 10 and 12. A majority (74.7% to 79.8%) of evolocumab-treated individuals achieved the goal of both an LDL-C < 1.4 mmol/L and an LDL-C reduction of at least 50%, > 75% achieved non-HDL-C < 2.2 mmol/L at the mean of weeks 10 and 12, and > 67% achieved ApoB < 65 mg/dL at week 12. Evolocumab effectively reduced LDL-C, non-HDL-C, ApoB, Lp(a), and remnant cholesterol in individuals with T2DM with and without AD. Evolocumab Q2W or QM enabled most individuals at high/very-high cardiovascular disease risk to achieve their LDL-C, non-HDL-C, and ApoB recommended goals.